Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...

PLYMOUTH MEETING, PA [September 12, 2022] — The National Comprehensive Cancer Network ® (NCCN ®) has published new NCCN Guidelines for Patients ®: Marginal Zone Lymphoma. A cancer of the lymphatic ...

Research at the European Hematology Association featured zanubrutinib as monotherapy and in combination with rituximab, and well as evaluations of biomarkers that signal responses. Zanubrutinib, the ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib, an investigational novel potent, highly selective, ...

This week, the FDA granted priority review to a supplemental new drug application (sNDA) for zanubrutinib (Brukinska) as a treatment option for adults with marginal zone lymphoma who have previously ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda This retrospective cohort study included patients ...

Outcomes in newly diagnosed diffuse large B cell lymphoma presenting with hepatic and/ or renal dysfunction. Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients ...

Combining PI3 kinase inhibitors with BTK inhibitors can mitigate side effects traditionally seen with PI3 kinase inhibitors, according to recent research. Traditionally, PI3 kinase inhibitors have ...

Please provide your email address to receive an email when new articles are posted on . Targeted therapies have rapidly changed the treatment landscape of indolent non-Hodgkin lymphoma, a heterogenous ...

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...